Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Mercy and Unity Cancer Center at Unity Hospital
mi
from
Fridley, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Mercy and Unity Cancer Center at Unity Hospital
mi
from
Fridley, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Hutchinson Area Health Care
mi
from
Hutchinson, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Hutchinson Area Health Care
mi
from
Hutchinson, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Meeker County Memorial Hospital
mi
from
Lichfield, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Meeker County Memorial Hospital
mi
from
Lichfield, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
HealthEast Cancer Care at St. John's Hospital
mi
from
Maplewood, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
HealthEast Cancer Care at St. John's Hospital
mi
from
Maplewood, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Minnesota Oncology Hematology, PA at Maplewood Cancer Center
mi
from
Maplewood, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Minnesota Oncology Hematology, PA at Maplewood Cancer Center
mi
from
Maplewood, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
mi
from
Minneapolis, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Hennepin County Medical Center - Minneapolis
mi
from
Minneapolis, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Hennepin County Medical Center - Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Hubert H. Humphrey Cancer Center at North Memorial Medical Center
mi
from
Robbinsdale, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Hubert H. Humphrey Cancer Center at North Memorial Medical Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Saint Francis Cancer Center
mi
from
Shakopee, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Saint Francis Cancer Center
mi
from
Shakopee, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
St. Joseph's Hospital
mi
from
St Paul, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
St. Joseph's Hospital
mi
from
St Paul, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Park Nicollet Health Services
mi
from
St. Louis Park, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Park Nicollet Health Services
mi
from
St. Louis Park, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Regions Hospital Cancer Care Center
mi
from
St. Paul, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Regions Hospital Cancer Care Center
mi
from
St. Paul, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
United Hospital
mi
from
St. Paul, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
United Hospital
mi
from
St. Paul, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Ridgeview Medical Center
mi
from
Waconia, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Ridgeview Medical Center
mi
from
Waconia, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Woodwinds Health Campus
mi
from
Woodbury, MN
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Woodwinds Health Campus
mi
from
Woodbury, MN
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Grandview Hospital
mi
from
Dayton, OH
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Grandview Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
David L. Rike Cancer Center at Miami Valley Hospital
mi
from
Dayton, OH
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
David L. Rike Cancer Center at Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
CCOP - Dayton
mi
from
Dayton, OH
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
CCOP - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Middletown Regional Hospital
mi
from
Middletown, OH
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Middletown Regional Hospital
mi
from
Middletown, OH
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Rapid City Regional Hospital
mi
from
Rapid City, SD
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Avera Cancer Institute
mi
from
Sioux Falls, SD
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated:  12/14/2016
Sioux Valley Hospital at University of South Dakota Medical Center
mi
from
Sioux Falls, SD
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System
Status: Enrolling
Updated: 12/14/2016
Sioux Valley Hospital at University of South Dakota Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma
Evaluation of the Safety and Immunogenicity of Intratumoral Injection of Interferon Gamma During Vaccination in Patients With Subcutaneous or Cutaneous Metastases of Melanoma
Status: Enrolling
Updated:  12/15/2016
University of Virginia
mi
from
Charlottesville, VA
Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma
Evaluation of the Safety and Immunogenicity of Intratumoral Injection of Interferon Gamma During Vaccination in Patients With Subcutaneous or Cutaneous Metastases of Melanoma
Status: Enrolling
Updated: 12/15/2016
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Status: Enrolling
Updated:  12/15/2016
University of Virginia
mi
from
Charlottesville, VA
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Status: Enrolling
Updated: 12/15/2016
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Advanced Melanoma
A Multipeptide Vaccine in Melanoma Patients With Evaluation of the Injection Site Microenvironment
Status: Enrolling
Updated:  12/15/2016
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Vaccine Therapy in Treating Patients With Advanced Melanoma
A Multipeptide Vaccine in Melanoma Patients With Evaluation of the Injection Site Microenvironment
Status: Enrolling
Updated: 12/15/2016
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
A Two-Arm, Single Center Pase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
Status: Enrolling
Updated:  12/28/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
A Two-Arm, Single Center Pase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
Status: Enrolling
Updated: 12/28/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
A Phase I/II Study of Concurrent Ipilimumab and Dabrafenib in Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  1/3/2017
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
A Phase I/II Study of Concurrent Ipilimumab and Dabrafenib in Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 1/3/2017
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Aurora, CO
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Atlanta, GA
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Lutherville, MD
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Lutherville, MD
Click here to add this to my saved trials
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
St. Louis, MO
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
New York, NY
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated:  1/4/2017
mi
from
Edegem,
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)
Status: Enrolling
Updated: 1/4/2017
mi
from
Edegem,
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
La Jolla, CA
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
New Haven, CT
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
New York, NY
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Research Site
mi
from
Parkville,
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Research Site
mi
from
Parkville,
Click here to add this to my saved trials
NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Real-Time NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Status: Enrolling
Updated:  2/2/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Real-Time NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Status: Enrolling
Updated: 2/2/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Real-Time NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Status: Enrolling
Updated:  2/2/2017
Brigham and Women's Hosp
mi
from
Boston, MA
NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Real-Time NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Status: Enrolling
Updated: 2/2/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  2/14/2017
Massachusetts General Hospital Mass General 2
mi
from
Boston, MA
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 2/14/2017
Massachusetts General Hospital Mass General 2
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  2/14/2017
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 2/14/2017
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  2/14/2017
Novartis Investigative Site
mi
from
Parkville,
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 2/14/2017
Novartis Investigative Site
mi
from
Parkville,
Click here to add this to my saved trials
Acromegaly Treatment Quality of Life Study
Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life
Status: Enrolling
Updated:  3/1/2017
Massachusetts General Hospital
mi
from
Boston, MA
Acromegaly Treatment Quality of Life Study
Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life
Status: Enrolling
Updated: 3/1/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials